June 11, 2019 04:36 PM IST
Motilal Oswal is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 800 in its research report dated May 18, 2019.
June 04, 2019 03:52 PM IST
HDFC Securities is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 915 in its research report dated May 19, 2019.
May 29, 2019 10:02 PM IST
ICICI Direct recommended is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 710 in its research report dated May 20, 2019.
May 23, 2019 11:12 PM IST
Dolat Capital is bullish on Jubilant Life Sciences has recommended Buy rating on the stock with a target price of Rs 750 in its research report dated May 21, 2019.
May 18, 2019 07:29 PM IST
May 18, 2019 07:19 PM IST
May 17, 2019 07:20 PM IST
Jubilant Life Sciences said its bottomline in the quarter was hit by a one time loan settlement with IFC, that resulted in an exceptional item of Rs 234.76 crore for the quarter ended March 31.
April 14, 2019 12:23 PM IST
Salisbury-based Jubilant Cadista Pharmaceuticals is a fully-owned subsidiary of Cadista Holdings, which is a part of Noida-based Jubilant Life Sciences.
April 12, 2019 01:15 PM IST
Net Sales are expected to increase by 3.8 percent Y-o-Y (down 1.7 percent Q-o-Q) to Rs. 2,336.5 crore, according to Prabhudas Lilladher.
March 22, 2019 11:20 AM IST
Company said FDA's announcement will not have any impact on the existing revenues from operations of this facility.
March 22, 2019 11:15 AM IST
Jubilant Life Sciences in a regulatory filing said it has been informed by the US Food and Drug Administration (USFDA) that inspection from December 10-18, 2018 at the Jubilant Generics Ltd API manufacturing facility, in Nanjangud, Mysore, has been classified as 'Official Action Indicated' (OAI).
March 20, 2019 11:27 AM IST
At 10:39 hrs, Jubilant Life Sciences was quoting Rs 791.10, down 6.01 percent on the NSE.
March 10, 2019 09:40 AM IST
The company is augmenting capacities at Roorkee to cater to increasing demand for generics from EU and ROW markets besides US markets.
March 08, 2019 03:12 PM IST
"The United States Food and Drug Administration (USFDA) may withhold approval of any new applications or supplements till the company addresses all issues raised by the agency," Jubilant Life Sciences said in a filing to the BSE.
March 08, 2019 01:30 PM IST
US revenues from the facility is about 4 percent of the total revenues of the company.
February 27, 2019 04:10 PM IST
ICICI Direct is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 905 in its research report dated February 05, 2019.
February 25, 2019 11:31 AM IST
JPL proposes to undertake meetings in Singapore (on February 26), Hong Kong and London (February 27) with one or more potential international institutional investors for the benchmark offering of the Notes.
February 08, 2019 03:38 PM IST
Dolat Capital is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 900 in its research report dated February 01, 2019.
February 01, 2019 06:38 PM IST
February 01, 2019 06:35 PM IST
February 01, 2019 05:15 PM IST
The company had posted a net profit of Rs 212.84 crore for the corresponding period of the previous fiscal, Jubilant Life Sciences said in a filing to BSE.
December 08, 2018 05:02 PM IST
The FDA has classified the inspection as 'Official Action Indicated', which means approvals of pending applications or supplements from this site maybe withheld.
December 05, 2018 03:42 PM IST
Motilal Oswal is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 965 in its research report dated December 04, 2018.
November 29, 2018 02:41 PM IST
The company's wholly-owned subsidiary has entered into a stock purchase agreement to acquire 534,194 shares of common stock of biotechnology firm Inipharm Inc USA, for a cash consideration of USD 534.20 per share, Jubilant Life Sciences said in a filing to BSE.
November 29, 2018 10:35 AM IST
Macquarie expects strong momentum in pharma segment to sustain going ahead and sees EPS CAGR of 25 percent over FY16-21.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
